Recent innovations in medicine often overturn the conventional understanding of disease management and patient care, and a remarkable case in point is the use of engineered bacteria as therapeutic agents. This fascinating new frontier is under sharp focus with Synlogic s publication of preclinical and clinical data for their experimental therapeutic SYNB1353.With the primary goal of developing a potential treatment for Classical Homocystinuria, a rare genetic metabolic disorder caused by an enzymatic defect in the methionine metabolic pathway resulting in elevated levels of homocysteine, Synlogic’s data has excited both researchers and clinicians. Currently, the standard care for homocystinuria involves di...

SYBX's Stock Performance relative to it's Customers

SYBX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Synlogic Inc	14.53	0.71	-0.64	1
SUBTOTAL	0.00	0.00	0.00	-

Sources: Synlogic Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Synlogic Inc’s corporate clients.
For your research, we’ve provided 9 tables on Synlogic Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.